Curated News
By: NewsRamp Editorial Staff
September 16, 2026
Oragenics to Present Concussion Drug ONP-002 at IPAC-RS 2026
TLDR
- Oragenics targets a market with no FDA-approved concussion drugs, giving ONP-002 a potential first-mover advantage.
- Oragenics uses a breath-powered intranasal device to deliver ONP-002 to the brain while minimizing systemic exposure.
- Oragenics advances ONP-002 as a potential first treatment for concussion, addressing a major unmet medical need.
- Oragenics will present ONP-002 data at the IPAC-RS 2026 Nasal Innovation Forum on September 17 in Jersey City.
Impact - Why it Matters
This news matters because concussion and mild traumatic brain injury affect millions worldwide, yet there are currently no FDA-approved pharmacological treatments. Oragenics’ ONP-002, with its innovative intranasal delivery, could become the first approved therapy, addressing a critical unmet need. The upcoming presentation and Phase IIa trial signal significant progress, offering hope to patients and potentially transformative value for investors. Moreover, the platform’s potential across other neurological conditions like Parkinson’s and Alzheimer’s highlights broader implications for brain health.
Summary
Oragenics (NYSE American: OGEN) is set to take center stage at the IPAC-RS 2026 Nasal Innovation Forum on Sept. 17 in Jersey City, New Jersey, where Chief Medical Officer James P. Kelly, MD, will present on the company’s groundbreaking intranasal neurosteroid candidate, ONP-002, for concussion. Kelly’s talk will delve into the development and clinical translation of ONP-002, highlighting its proposed mechanism of action and Oragenics’ proprietary breath-powered intranasal delivery device, which is engineered to target the brain while minimizing systemic exposure. This presentation comes as Oragenics advances its Phase IIa feasibility trial, currently enrolling at three sites in Australia, and prepares for anticipated U.S. development, including an Investigational New Drug application submission expected in the fourth quarter of 2026. Completed Phase I single and multiple ascending-dose trials have already demonstrated a favorable safety and tolerability profile, underscoring the potential of ONP-002 in a space where no FDA-approved pharmacological treatments exist for mild traumatic brain injury.
Oragenics, Inc. is a clinical-stage biotechnology company dedicated to developing brain-targeted therapeutics through its proprietary intranasal delivery technology. The company is focused on advancing ONP-002 as a potential first-in-class treatment for concussion and mild traumatic brain injury, with clinical trials commencing in Australia and U.S. Phase 2b trials planned to follow. Beyond concussion, Oragenics’ intranasal platform holds promise for multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders. For more information, visit oragenics.com. The latest updates on OGEN can be found in the company’s newsroom at https://ibn.fm/OGEN. This news was distributed by InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics to Present Concussion Drug ONP-002 at IPAC-RS 2026
